- Home
- UXIN vs OCS Comparison
UXIN vs OCS Comparison
Compare UXIN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UXIN
- OCS
- Stock Information
- Founded
- UXIN 2011
- OCS 2003
- Country
- UXIN China
- OCS Switzerland
- Employees
- UXIN N/A
- OCS N/A
- Industry
- UXIN Business Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- UXIN Consumer Discretionary
- OCS Health Care
- Exchange
- UXIN Nasdaq
- OCS Nasdaq
- Market Cap
- UXIN 744.3M
- OCS 717.3M
- IPO Year
- UXIN 2018
- OCS N/A
- Fundamental
- Price
- UXIN $4.28
- OCS $17.45
- Analyst Decision
- UXIN
- OCS Strong Buy
- Analyst Count
- UXIN 0
- OCS 5
- Target Price
- UXIN N/A
- OCS $29.20
- AVG Volume (30 Days)
- UXIN 203.8K
- OCS 39.4K
- Earning Date
- UXIN 11-25-2024
- OCS 11-07-2024
- Dividend Yield
- UXIN N/A
- OCS N/A
- EPS Growth
- UXIN N/A
- OCS N/A
- EPS
- UXIN N/A
- OCS N/A
- Revenue
- UXIN $232,096,942.00
- OCS $1,027,571.00
- Revenue This Year
- UXIN $26.86
- OCS $6.87
- Revenue Next Year
- UXIN N/A
- OCS $884.16
- P/E Ratio
- UXIN N/A
- OCS N/A
- Revenue Growth
- UXIN 11.56
- OCS N/A
- 52 Week Low
- UXIN $1.41
- OCS $10.11
- 52 Week High
- UXIN $8.40
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- UXIN 46.62
- OCS 69.31
- Support Level
- UXIN $3.91
- OCS $15.45
- Resistance Level
- UXIN $4.49
- OCS $17.92
- Average True Range (ATR)
- UXIN 0.52
- OCS 0.55
- MACD
- UXIN -0.05
- OCS 0.17
- Stochastic Oscillator
- UXIN 22.50
- OCS 83.09
About UXIN Uxin Limited ADS
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.